OTC Markets OTCID
USD
Avenue Therapeutics, Inc. (ATXI)
0.4279
+0.0479
(+12.60%)
At close: October 30 at 4:00:00 PM EDT
Key Executives
Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Alexandra MacLean M.D.
|
CEO & Director | 434k | -- | 1968 |
|
Mr. David Jin
|
Interim CFO, COO & Corporate Secretary | -- | -- | 1990 |
|
Dr. Lindsay Allan Rosenwald M.D.
|
Executive Director | -- | -- | 1955 |
Avenue Therapeutics, Inc.
1111 Kane Concourse
Suite 301
Bay Harbor Islands, FL 33154
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
Corporate Governance
Avenue Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of
Institutional Shareholder Services (ISS)
Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
December 15, 2025 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
